1. 17LBA Results from an open-label, randomized, controlled Phase 3 study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic RCC. (September 2015) Authors: Rini, B.; Stenzl, A.; Zdrojowy, R.; Kogan, M.; Shkolnik, M.; Oudard, S.; Weikert, S.; Bracarda, S.; Crabb, S.; Bedke, J.; Ludwig, J.; Maurer, D.; Mendrzyk, R.; Mahr, A.; Fritsche, J.; Weinschenk, T.; Singh, H.; Kirner, A.; Reinhardt, C.; Eisen, T. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S718 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 354 Phase I study of investigational oral mTORC1/2 inhibitor MLN0128: Expansion phase in patients with renal, endometrial, or bladder cancer. (September 2015) Authors: Voss, M.; Gordon, M.S.; Mita, M.; Rini, B.; Makker, V.; Macarulla, T.; Smith, D.; Kwak, E.L.; Cervantes, A.; Puzanov, I.; Pili, R.; Wang, D.; Jalal, S.; Pant, S.; Patel, M.; Neuwirth, R.; Zohren, F.; Infante, J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S72 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 4LBA Cabozantinib versus everolimus in patients with advanced renal cell carcinoma: Results of the randomized phase 3 METEOR trial. (September 2015) Authors: Choueiri, T.; Escudier, B.; Powles, T.; Mainwaring, P.; Rini, B.; Donskov, F.; Hammers, H.; Hutson, T.; Roth, B.; Peltola, K.; Lee, J.L.; Heng, D.; Schmidinger, M.; Borgman-Hagey, A.; Hessel, C.; Scheffold, C.; Schwab, G.; Tannir, N.; Motzer, R. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S708 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗